{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:55:39Z","timestamp":1770281739540,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Aerospace Science Foundation of China","award":["81972204, 81702327"],"award-info":[{"award-number":["81972204, 81702327"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10067-020-05272-4","type":"journal-article","created":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T04:52:55Z","timestamp":1594443175000},"page":"683-692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials"],"prefix":"10.1007","volume":"40","author":[{"given":"Meida","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingcheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8146-8374","authenticated-orcid":false,"given":"Xuefeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieruo","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,11]]},"reference":[{"issue":"4","key":"5272_CR1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3810\/psm.2011.11.1946","volume":"39","author":"M Hamburger","year":"2011","unstructured":"Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, Doghramji PP, Guadagnoli GA, Hamburger F, Harford R, Lieberman JA 3rd, Mandel DR, Mandelbrot DA, McClain BP, Mizuno E, Morton AH, Mount DB, Pope RS, Rosenthal KG, Setoodeh K, Skosey JL, Edwards NL (2011) 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Phys Sportsmed 39(4):98\u2013123","journal-title":"Phys Sportsmed"},{"issue":"3","key":"5272_CR2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s10067-017-3753-z","volume":"37","author":"E Jia","year":"2018","unstructured":"Jia E, Zhu J, Huang W, Chen X, Li J (2018) Dual-energy computed tomography has limited diagnostic sensitivity for short-term gout. Clin Rheumatol 37(3):773\u2013777","journal-title":"Clin Rheumatol"},{"key":"5272_CR3","doi-asserted-by":"crossref","first-page":"810","DOI":"10.12659\/MSM.895749","volume":"22","author":"L Xu","year":"2016","unstructured":"Xu L, Liu S, Guan M, Xue Y (2016) Comparison of prednisolone, etoricoxib, and indomethacin in treatment of acute gouty arthritis: an open-label, randomized, controlled trial. Med Sci Monit 22:810\u2013817","journal-title":"Med Sci Monit"},{"issue":"6","key":"5272_CR4","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/15257770802136040","volume":"27","author":"JG Puig","year":"2008","unstructured":"Puig JG, de Miguel E, Castillo MC, Rocha AL, Martinez MA, Torres RJ (2008) Asymptomatic hyperuricemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids 27(6):592\u2013595","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"2","key":"5272_CR5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/art.23121","volume":"58","author":"AG Ioachimescu","year":"2008","unstructured":"Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ (2008) Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 58(2):623\u2013630","journal-title":"Arthritis Rheum"},{"issue":"1","key":"5272_CR6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrrheum.2012.143","volume":"9","author":"KL Rock","year":"2013","unstructured":"Rock KL, Kataoka H, Lai JJ (2013) Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol 9(1):13\u201323","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"5272_CR7","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00296-019-04342-4","volume":"22","author":"J Wu","year":"2019","unstructured":"Wu J, Zhang YP, Qu Y, Jie LG, Deng JX, Yu QH (2019) Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients. Int J Rheum Dis 22(8):1445\u20131451","journal-title":"Int J Rheum Dis"},{"issue":"7","key":"5272_CR8","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","volume":"57","author":"F Perez-Ruiz","year":"2007","unstructured":"Perez-Ruiz F, Liote F (2007) Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 57(7):1324\u20131328","journal-title":"Arthritis Rheum"},{"issue":"10","key":"5272_CR9","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R, American College of R (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64(10):1431\u20131446","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"5272_CR10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Liote F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29\u201342","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5272_CR11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","volume":"27","author":"F Arellano","year":"1993","unstructured":"Arellano F, Sacristan JA (1993) Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 27(3):337\u2013343","journal-title":"Ann Pharmacother"},{"issue":"4","key":"5272_CR12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrrheum.2015.132","volume":"12","author":"LK Stamp","year":"2016","unstructured":"Stamp LK, Day RO, Yun J (2016) Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheumatol 12(4):235\u2013242","journal-title":"Nat Rev Rheumatol"},{"issue":"16","key":"5272_CR13","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","volume":"76","author":"Y Takano","year":"2005","unstructured":"Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA (2005) Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase. Life Sci 76(16):1835\u20131847","journal-title":"Life Sci"},{"issue":"8\u20139","key":"5272_CR14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1081\/NCN-200027377","volume":"23","author":"S Hoshide","year":"2004","unstructured":"Hoshide S, Takahashi Y, Ishikawa T, Kubo J, Tsuchimoto M, Komoriya K, Ohno I, Hosoya T (2004) PK\/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids 23(8\u20139):1117\u20131118","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"1","key":"5272_CR15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00045391-200501000-00005","volume":"12","author":"MD Mayer","year":"2005","unstructured":"Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ (2005) Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 12(1):22\u201334","journal-title":"Am J Ther"},{"issue":"5","key":"5272_CR16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40266-017-0461-y","volume":"34","author":"ED Deeks","year":"2017","unstructured":"Deeks ED (2017) Lesinurad: a review in hyperuricaemia of gout. Drugs Aging 34(5):401\u2013410","journal-title":"Drugs Aging"},{"key":"5272_CR17","doi-asserted-by":"crossref","unstructured":"Huneycutt E, Board C, Clements JN (2018) Lesinurad, a selective URAT-1 inhibitor with a novel mechanism in combination with a xanthine oxidase inhibitor, for hyperuricemia associated with gout. J Pharm Pract 31(6):670\u2013677","DOI":"10.1177\/0897190017734427"},{"issue":"11","key":"5272_CR18","first-page":"1106","volume":"38","author":"JY Wu","year":"2018","unstructured":"Wu JY, Chang YT, Lin YC, Lee CH, Loh EW, Wu MY, Chang YS, Tam KW (2018) Efficacy and safety of lesinurad in patients with hyperuricemia associated with gout: a systematic review and meta-analysis of randomized controlled trials. PLoS One 38(11):1106\u20131119","journal-title":"PLoS One"},{"issue":"4","key":"5272_CR19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/096228020101000404","volume":"10","author":"AJ Sutton","year":"2001","unstructured":"Sutton AJ, Abrams KR (2001) Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 10(4):277\u2013303","journal-title":"Stat Methods Med Res"},{"issue":"7521","key":"5272_CR20","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","volume":"331","author":"DM Caldwell","year":"2005","unstructured":"Caldwell DM, Ades AE, Higgins JP (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331(7521):897\u2013900","journal-title":"BMJ"},{"issue":"20","key":"5272_CR21","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23(20):3105\u20133124","journal-title":"Stat Med"},{"issue":"11","key":"5272_CR22","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\u00e1-L\u00f3pez F, G\u00f8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784","journal-title":"Ann Intern Med"},{"key":"5272_CR23","unstructured":"Higgins J, Green S (2011) Cochrane handbook of systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from http:\/\/www.cochrane-handbook.org\/. Accessed 31 May 2020"},{"issue":"1","key":"5272_CR24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.chest.2016.08.1476","volume":"151","author":"BC Zhao","year":"2017","unstructured":"Zhao BC, Huang TY, Deng QW, Liu WF, Liu J, Deng WT, Liu KX, Li C (2017) Prophylaxis against atrial fibrillation after general thoracic surgery: trial sequential analysis and network meta-analysis. Chest 151(1):149\u2013159","journal-title":"Chest"},{"issue":"2","key":"5272_CR25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64(2):163\u2013171","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"5272_CR26","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","volume":"76","author":"T Bardin","year":"2017","unstructured":"Bardin T, Keenan RT, Khanna PP, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, So A (2017) Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis 76(5):811\u2013820","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"5272_CR27","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353(23):2450\u20132461","journal-title":"N Engl J Med"},{"issue":"3","key":"5272_CR28","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","volume":"52","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N (2005) Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 52(3):916\u2013923","journal-title":"Arthritis Rheum"},{"issue":"2","key":"5272_CR29","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12(2):R63","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"5272_CR30","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","volume":"69","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, Adler S, Fung M, Storgard C, Baumgartner S, Perez-Ruiz F (2017) Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis Rheumatol 69(9):1903\u20131913","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"5272_CR31","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/art.40233","volume":"69","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth N, Saag KG, Palmer WE, Choi HK, Hunt B, MacDonald PA, Thienel U, Gunawardhana L (2017) Effects of febuxostat in early gout: a randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 69(12):2386\u20132395","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"5272_CR32","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/annrheumdis-2015-207919","volume":"75","author":"F Perez-Ruiz","year":"2016","unstructured":"Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C (2016) Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis 75(6):1074\u20131080","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5272_CR33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","volume":"69","author":"KG Saag","year":"2017","unstructured":"Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, Becker MA (2017) Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheumatol 69(1):203\u2013212","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"5272_CR34","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/art.39654","volume":"68","author":"KG Saag","year":"2016","unstructured":"Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L (2016) Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment. Arthritis Rheumatol 68(8):2035\u20132043","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"5272_CR35","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59(11):1540\u20131548","journal-title":"Arthritis Rheum"},{"issue":"12","key":"5272_CR36","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","volume":"56","author":"AK Tausche","year":"2017","unstructured":"Tausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, Adler S, Bhakta N, Storgard C, Baumgartner S, Saag K (2017) Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Rheumatology (Oxford) 56(12):2170\u20132178","journal-title":"Rheumatology (Oxford)"},{"issue":"4(special)","key":"5272_CR37","first-page":"1623","volume":"31","author":"S Wang","year":"2018","unstructured":"Wang S (2018) The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia. Pharmacotherapy 31(4(special)):1623\u20131627","journal-title":"Pharmacotherapy"},{"issue":"6","key":"5272_CR38","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1756-185X.12648","volume":"18","author":"S Xu","year":"2015","unstructured":"Xu S, Liu X, Ming J, Chen S, Wang Y, Liu X, Liu H, Peng Y, Wang J, Lin J, Ji H, Liu B, Lu Y, Liu P, Zhang Y, Ji Q (2015) A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. Int J Rheum Dis 18(6):669\u2013678","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"5272_CR39","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3109\/03009742.2015.1099729","volume":"45","author":"KH Yu","year":"2016","unstructured":"Yu KH, Lai JH, Hsu PN, Chen DY, Chen CJ, Lin HY (2016) Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. Scand J Rheumatol 45(4):304\u2013311","journal-title":"Scand J Rheumatol"},{"key":"5272_CR40","doi-asserted-by":"crossref","unstructured":"Zhang F, Liu Z, Jiang L, Zhang H, Zhao D, Li Y, Zou H, Wang X, Li X, Shi B, Xu J, Yang H, Hu S, Qu S (2019) A randomized, double-blind, non-inferiority study of febuxostat versus allopurinol in hyperuricemic Chinese subjects with or without gout. Rheumatol Ther 6(4):543\u2013557","DOI":"10.1007\/s40744-019-00173-8"},{"issue":"2","key":"5272_CR41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clinthera.2012.12.011","volume":"35","author":"P Ye","year":"2013","unstructured":"Ye P, Yang S, Zhang W, Lv Q, Cheng Q, Mei M, Luo T, Liu L, Chen S, Li Q (2013) Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. Clin Ther 35(2):180\u2013189","journal-title":"Clin Ther"},{"issue":"3","key":"5272_CR42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.semarthrit.2013.05.004","volume":"43","author":"LI Faruque","year":"2013","unstructured":"Faruque LI, Ehteshami-Afshar A, Wiebe N, Tjosvold L, Homik J, Tonelli M (2013) A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin Arthritis Rheum 43(3):367\u2013375","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"5272_CR43","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40265-015-0360-7","volume":"75","author":"JE Frampton","year":"2015","unstructured":"Frampton JE (2015) Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout. Drugs 75(4):427\u2013438","journal-title":"Drugs"},{"key":"5272_CR44","volume":"11","author":"JH Tayar","year":"2012","unstructured":"Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME (2012) Febuxostat for treating chronic gout. Cochrane Database Syst Rev 11:CD008653","journal-title":"Cochrane Database Syst Rev"},{"key":"5272_CR45","doi-asserted-by":"crossref","first-page":"33082","DOI":"10.1038\/srep33082","volume":"6","author":"S Li","year":"2016","unstructured":"Li S, Yang H, Guo Y, Wei F, Yang X, Li D, Li M, Xu W, Li W, Sun L, Gao Y, Wang Y (2016) Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. Sci Rep 6:33082","journal-title":"Sci Rep"},{"key":"5272_CR46","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/rheumatology\/kex065","volume":"56","author":"T Zhang","year":"2017","unstructured":"Zhang T, Pope JE (2017) Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. Rheumatology (Oxford) 56:1144\u20131153","journal-title":"Rheumatology (Oxford)"},{"key":"5272_CR47","doi-asserted-by":"crossref","first-page":"1076189","DOI":"10.1155\/2019\/1076189","volume":"2019","author":"JA Cuenca","year":"2019","unstructured":"Cuenca JA, Balda J, Palacio A, Young L, Pillinger MH, Tamariz L (2019) Febuxostat and cardiovascular events: a systematic review and meta-analysis. Int J Rheumatol 2019:1076189","journal-title":"Int J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05272-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05272-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05272-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T23:37:47Z","timestamp":1625960267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05272-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,11]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["5272"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05272-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,11]]},"assertion":[{"value":"2 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}